Merck and Daiichi Sankyo voluntarily withdrew their Biologics License Application for a lung cancer drug (ifinatamab deruxtecan) after the FDA indicated the data did not meet accelerated approval requirements. This is a setback for the drug's near-term market entry, though ongoing Phase 3 trials continue.
Merck and Daiichi Sankyo have pulled their FDA application for ifinatamab deruxtecan, a lung cancer treatment, due to insufficient data for accelerated approval. This is a significant setback as it delays the potential market entry of a promising drug for extensive-stage small cell lung cancer. While the companies will continue with Phase 3 trials, the immediate revenue potential from accelerated approval is lost. This primarily affects Merck and Daiichi Sankyo, potentially leading to short-term negative sentiment and pressure on their stock prices, as investors re-evaluate the timeline and probability of success for this particular drug. The long-term implications depend on the success of the ongoing Phase 3 trials.